Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (4) : 978-987     DOI: 10.14336/AD.2019.0910
Review |
Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus
Ma Wei-Xing1,2,3, Tang Jing3, Lei Zhi-Wen3, Li Chun-Yan1,4, Zhao Li-Qing3, Lin Chao3, Sun Tao3, Li Zheng-Yi3, Jiang Ying-Hui3, Jia Jun-Tao3, Liang Cheng-Zhu3, Liu Jun-Hong2, Yan Liang-Jun1,*
1Department of Pharmaceutical, University of North Texas Health Science Center, Fort Worth, Texas, USA
2Chemical Engineering Institute, Qingdao University of Science and Technology, Qingdao, Shandong, China
3Technological Center, Qingdao Customs, Qingdao, Shandong, China
4Shantou University Medical College, Shantou, Guangdong, China
Download: PDF(595 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

The goal of this review was to summarize current biochemical mechanisms of and risk factors for diabetic brain injury. We mainly summarized mechanisms published in the past three years and focused on diabetes induced cognitive impairment, diabetes-linked Alzheimer’s disease, and diabetic stroke. We think there is a need to conduct further studies with increased sample sizes and prolonged period of follow-ups to clarify the effect of DM on brain dysfunction. Additionally, we also think that enhancing experimental reproducibility using animal models in conjunction with application of advanced devices should be considered when new experiments are designed. It is expected that further investigation of the underlying mechanisms of diabetic cognitive impairment will provide novel insights into therapeutic approaches for ameliorating diabetes-associated injury in the brain.

Keywords diabetes      brain      cognitive impairment      Alzheimer’s disease      stroke     
Corresponding Authors: Yan Liang-Jun   
About author:

These authors contributed equally to this work.

Just Accepted Date: 23 September 2019   Issue Date: 30 July 2020
E-mail this article
E-mail Alert
Articles by authors
Ma Wei-Xing
Tang Jing
Lei Zhi-Wen
Li Chun-Yan
Zhao Li-Qing
Lin Chao
Sun Tao
Li Zheng-Yi
Jiang Ying-Hui
Jia Jun-Tao
Liang Cheng-Zhu
Liu Jun-Hong
Yan Liang-Jun
Cite this article:   
Ma Wei-Xing,Tang Jing,Lei Zhi-Wen, et al. Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus[J]. Aging and disease, 2020, 11(4): 978-987.
URL:     OR
Figure 1.  Signaling pathways and risk factors that are potentially involved in development of cognitive impairment induced by diabetes.
Figure 2.  Signaling pathways and risk factors that are potentially involved in diabetic AD.
Figure 3.  Signaling pathways and risk factors potentially involved in diabetic stroke.
[1] Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MrLF, et al. (2009). (Pre) diabetes, brain aging, and cognition. Biochim Biophys Acta, 1792:432-443.
[2] Toth C (2014). Chapter 32-Diabetes and neurodegeneration in the brain. Handbook of Clinical Neurology, 126:489-511.
[3] Guo S, Deng W, Xing C, Zhou Y, Ning M, Lo EH (2019). Effects of aging, hypertension and diabetes on the mouse brain and heart vasculomes. Neurobiol Dis, 126:117-123.
[4] Eisenhut M (2018). In diabetic ketoacidosis brain injury including cerebral oedema and infarction is caused by interleukin-1. Med Hypotheses, 121:44-46.
[5] Vargas R, Rincón J, Pedreañez A, Viera N, Hernández-Fonseca JP, Peña C, et al. (2012). Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats. Brain Res, 1453:64-76.
[6] Wisse LEM, Bresser Jd, Geerlings MI, Reijmer YD, Portegies MLP, Brundel M, et al. (2014). Global brain atrophy but not hippocampal atrophy is related to type 2 diabetes. J Neurol Sci, 344:32-36.
[7] Wrighten SA, Piroli GG, Grillo CA, Reagan LP (2009). A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta, 2009:444-453.
[8] Biessels GJ, Heide LPvd, Kamal A, Bleys RLAW, Gispen WH (2002). Ageing and diabetes: implications for brain function. Eur J Pharmacol, 441:1-14.
[9] Chen Z, Li L, Sun J, Ma L (2012). Mapping the brain in type II diabetes: Voxel-based morphometry using DARTEL. Eur J Radiol, 81:1870-1876.
[10] Thibault O, Anderson KL, DeMoll C, Brewer LD, Landfield PW, Porter NM (2013). Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. Eur J Pharmacol, 719:34-43.
[11] Schoenemann PT (2006). Evolution of the Size and Functional Areas of the Human Brain. Annu Rev Anthropol, 35:379-406.
[12] Rosenberg J, Lechea N, Pentang GN, Shah NJ (2019). What magnetic resonance imaging reveals - A systematic review of the relationship between type II diabetes and associated brain distortions of structure and cognitive functioning. Front Neuroendocrinol, 52:79-112.
[13] Cameron FJ (2015). The Impact of Diabetes on Brain Function in Childhood and Adolescence. Pediatr Clin N Am, 62:911-927.
[14] Hughes TM, Sink KM, Williamson JD, Hugenschmidt CE, Wagner BC, Whitlow CT, et al. (2018). Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes. Journal of Diabetes and Its Complications, 32:916-921.
[15] Bancks MP, Alonso A, Gottesman RF, Mosley TH (2017). Brain function and structure and risk for incident diabetes:The Atherosclerosis Risk in Communities Study. Alzheimer's & Dementia: the Journal of the Alzheimer's Association, 13:1345-1354.
[16] Groeneveld O, Reijmer Y, Heinen R, Kuijf H, Koekkoek P, Janssen J, et al. (2018). Brain imaging correlates of mild cognitive impairment and early dementia in patients with type 2 diabetes mellitus. Nutrition, Metabolism & Cardiovascular Diseases, 28:1253-1260.
[17] Hansen TM, Brock B, Juhl A, Drewes AM, Vorum H, Andersen CU, et al. (2019). Brain spectroscopy reveals that N-acetylaspartate is associated to peripheral sensorimotor neuropathy in type 1 diabetes. Journal of Diabetes and Its Complications, 33:323-328.
[18] Ergula A, Valenzuela JP, Fouda AY, Fagan SC (2015). Cellular connections, microenvironment and brain angiogenesis in diabetes: Lost communication signals in the post-stroke period. Brain Res, 1623:81-96.
[19] Arnal E, Miranda M, Johnsen-Soriano S, J Romero F (2014). The Anti-Oxidative Component of Docosahexaenoic Acid (DHA) in the Brain in Diabetes. Diabetes: Oxidative Stress and Dietary Antioxidants, Chapter 13:129-134.
[20] Kooistra M, Geerlings MI, Mali WPTM, Vincken KL, Graaf Yvd, Biessels GJ (2013). Diabetes mellitus and progression of vascular brain lesions and brain atrophy in patients with symptomatic atherosclerotic disease. The SMART-MR study. J Neurol Sci, 332:69-74.
[21] MD FJC, Northam EA, Ryan CM (2019). The effect of type 1 diabetes on the developing brain. The Lancet Child & Adolescent Health, 3:427-436.
[22] Shahid MH, Verma A, Youngblood L (2018). From Mechanical to Chemical: A Case of Diabetes Insipidus Induced by Concussive Brain Injury. Am J Med, 131:e293-e294.
[23] Wu Y, Ye L, Yuan Y, Jiang T, Guo X, Wang Z, et al. (2019). Autophagy Activation is Associated with Neuroprotection in Diabetes-associated Cognitive Decline. Aging Dis, 10:1-13
[24] Park SY, Kim HY, Lee YS, Heo HJ, Shin HK, Lee WS, et al. (2019). Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model. Behav Brain Res, 365:133-140.
[25] MA A, Kumar MKM, Sabitha M, Menon KK, Nair SC (2019). Nanotechnology approaches for enhanced CNS delivery in treating T Alzheimer's disease. J Drug Deliv Sci Tec, 51:297-309.
[26] Macpherson H, Formica M, Harris E, Daly RM (2017). Brain functional alterations in Type 2 Diabetes - A systematic review of fMRI studies. Front Neuroendocrinol, 47:34-46.
[27] Song H-D, Kim SN, Saha A, Ahn S-Y, Akindehin S, Son Y, et al. (2020). Aging-Induced Brain-Derived Neurotrophic Factor in Adipocyte Progenitors Contributes to Adipose Tissue Dysfunction. Aging Dis, 11:1-13.
[28] Yang L, Yuan J, Zhou Z (2014). Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus. Can J Diabetes, 38:473-479.
[29] Qiao J, Li L, Ma Y, Shi R, Teng M (2018). Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice. Curr Res Translational Med, 67:89-92.
[30] Abdelwaheda OM, Tork OM, Din MMGe, L Rashedb MZ (2018). Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive T functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin. Brain Res Bull, 139:67-80.
[31] Zheng T, Liu H, Qin L, Chen B, Zhang X, Hu X, et al. (2018). Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metab, 87:105-112.
[32] Chandran R, Kumar M, Kesavan L, Jacob RS, Gunasekaran S, Lakshmi S, et al. (2019). Cellular calcium signaling in the aging brain. J Chem Neuroanat, 95:95-114.
[33] Navakkode S, Liu C, Soong TW (2018). Altered function of neuronal L-type calcium channels in ageing and neuroinflammation:Implications in age-related synaptic dysfunction and cognitive decline. Aging Res Rev, 42:86-99.
[34] Grützner TM, Listunova L, Fabian GA, Kramer BA, Flach D, Weisbrod M, et al. (2018). Serum calcium levels and neuropsychological performance in depression and matched healthy controls: Reversal of correlation a marker of the aging cognitive clock? Psychoneuroendocrino, 91:198-205.
[35] Sharma A, Schray A, Bartolovic M, Roesch-Ely D, Aschenbrenner S, Weisbrod M (2017). Relationship between serum calcium and neuropsychological performance might indicate etiological heterogeneity underlying cognitive deficits in schizophrenia and depression. Psychiatry Res, 252:80-86.
[36] Ahn C, Kang J-H, Jeung E-B (2017). Calcium homeostasis in diabetes mellitus. J Vet Sci, 18:261-266.
[37] Arruda AP, Hotamisligil GS (2015). Calcium Homeostasis and Organelle Function in the Pathogenesis of Obesity and Diabetes. Cell Metab, 22:381-397.
[38] Ouyang L, Zhang W, Du G, Liu H, Xie J, Gu J, et al. (2019). Lead Exposure-Induced Cognitive Impairment through RyR-Modulating Intracellular Calcium Signaling in Aged Rats. Toxicology, 419:55-64.
[39] Underwood M, Sivesind P, Gabourie T (2011). Effect of apoaequorin on cognitive function. Alzheimer's & Dementia, 7:e65.
[40] Milgram NW, Landsberg G, Merrick D, Underwood MY (2015). A novel mechanism for cognitive enhancement in aged dogs with the use of a calcium-buffering protein. J Vet Behav, 10:217-222.
[41] Nicholls DG (2017). Brain mitochondrial calcium transport: Origins of the set-point concept and its application to physiology and pathology. Neurochem Int, 109:5-12.
[42] Workgroup AsACH (2017). Calcium Hypothesis of Alzheimer’s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimer’s & Dementia, 13:178-182.
[43] Rossi A, Pizzo P, Filadi R (2019). Calcium, mitochondria and cell metabolism: A functional triangle in bioenergetics. BBA-Mol Cell Res, 1866:1068-1078.
[44] Guerrero-Hernandez A, Verkhratsky A (2014). Calcium signalling in diabetes. Cell Calcium, 56:297-301.
[45] Jaworska A, Dzbek J, Styczynska M, Kuznicki J (2013). Analysis of calcium homeostasis in fresh lymphocytes from patients with sporadic Alzheimer's disease or mild cognitive impairment. BBA-Mol Cell Res, 1833:1692-1699.
[46] Gray SM, J Barrett E (2018). Chapter 11 - The Blood-Brain Barrier in Diabetes Mellitus. Type 2 Diabetes and Dementia:211-229.
[47] Jiang X, Andjelkovic AV, Zhu L, Yang T, Bennett MVL, Chen J, et al. (2018). Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol, 163-164:144-171.
[48] Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A (2018). Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun, 91:34-44.
[49] Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. (2018). Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer's & Dementia, 14:1640-1650.
[50] Duarte-Delgado NP, Vásquez G, Ortiz-Reyes BL (2019). Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Autoimmun Rev, 18:426-432.
[51] Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, et al. (2019). Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacol Res, 141:291-297.
[52] Xu Z, Zeng Wen, Sun J, Chen W, Zhang R, Yang Z, et al. (2017). The quantification of blood-brain barrier disruption using dynamic contrast-enhanced magnetic resonance imaging in aging rhesus monkeys with spontaneous type 2 diabetes mellitus. NeuroImage, 158:480-487.
[53] Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C, Group tSBS, et al. (2017). Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging, 51:104-112.
[54] C Lim D, I Packa A (2014). Obstructive sleep apnea and cognitive impairment: Addressing the blood-brain barrier. Sleep Med Rev, 18:35-48.
[55] Mohamed NA, Gawad HSA (2017). Taurine dietary supplementation attenuates brain, thyroid, testicular disturbances and oxidative stress in streptozotocin-induced diabetes mellitus in male rats. Beni-Suef University Journal of Basic and Applied Sciences, 6:247-252.
[56] Kunze R, H Marti H (2019). Angioneurins - Key regulators of blood-brain barrier integrity during hypoxic and ischemic brain injury. Prog Neurobiol, 178:1-29.
[57] Zhang S, Dong H, Zhang X, Li N, Sun J, Qian Y (2016). Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption. Behav Brain Res, 298:158-166.
[58] Patell R, Nigmatoulline D, Bena J, Kim DG, Messinger-Rapport B, Lansang MC (2017). Hyperglycemia and Hypoglycemia in Patients with Diabetes in Skilled Nursing Facilities. Endocr Pr, 23:458-465.
[59] Tourkmani AM, Alharbi TJ, Rsheed AMB, AlRasheed AN, AlBattal SM, Abdelhay O, et al. (2018). Hypoglycemia in Type 2 Diabetes Mellitus patients: A review article. Diabetes & Metabolic Syndrome: Clin Res Rev, 12:791-794.
[60] Wiegers EC, Becker KM, Rooijackers HM, Samson-Himmelstjerna FCv, Tack CJ, Heerschap A, et al. (2016). Cerebral blood flow response to hypoglycemia is altered in patients with type 1 diabetes and impaired awareness of hypoglycemia. J Cereb Blood Flow Metab, 37:1994-2001.
[61] Sheen Y-J, Sheu WHH (2016). Association between hypoglycemia and dementia in patients with type 2 dia- betes. Diabetes Res Clin Pr, 116:279-287.
[62] Yuan L, Lingling Z, Ling C, Liting C, Hao L, Huiping L, et al. (2017). Correlation between blood glucose fluctuation and brain damage in neonates with hypoglycemia. J Clin Pediatr, 35:652-654.
[63] Shukla V, Shakya AK, Perez-Pinzon MA, Dave KR (2017). Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation, 14:1-22.
[64] Rehni AK, Dave KR (2018). Impact of Hypoglycemia on Brain Metabolism During Diabetes. Mol Neurobiol, 55:9075-9088.
[65] Xi C, Pan C, Li T (2018). Abnormally low Bispectral index and severe hypoglycemia during maintenance of and recovery from general anesthesia in diabetic retinopathy surgery: two case reports. BMC Anesthesiology, 18:1-4.
[66] Hwang JJ, Parikh L, Lacadie C, Seo D, Lam W, Hamza M, et al. (2018). Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest, 128:1485-1495.
[67] Jackson DA, Michael T, Abreu AVd, Agrawal R, Bortolato M, Fisher SJ (2018). Prevention of Severe Hypoglycemia-Induced Brain Damage and Cognitive Impairment with Verapamil. Diabetes, 67:2107-2112.
[68] Rehni AK, Shukla V, Perez-Pinzon MA, Dave KR (2018). Acidosis mediates recurrent hypoglycemia-induced increase in ischemic brain injury in treated diabetic rats. Neuropharmacology, 135:192-201.
[69] Faiq MA, Dada R, Saluja D, Dada T (2014). Glaucoma-Diabetes of the brain: A radical hypothesis about its nature and pathogenesis. Med Hypotheses, 82:535-546.
[70] Kandimalla R, Thirumala V, Reddy PH (2017). Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta, 1863:1078-1089.
[71] Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, et al. (2017). Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study. Alzheimer’s & Dementia, 13:1327-1336.
[72] Domínguez RO, Pagano MA, Marschoff ER, González SE, Repetto MG, Serra JA (2014). Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. Neurología, 29:567-572.
[73] Pardeshi R, Bolshette N, Gadhave K, Ahire A, Ahmed S, Cassano T, et al. (2017). Insulin signaling: An opportunistic target to minify the risk of Alzheimer’s disease. Psychoneuroendocrinology, 83:159-171.
[74] Beheshti I, Mishra S, Sone D, Khanna P, Matsuda H (2020). T1-weighted MRI-driven Brain Age Estimation in Alzheimer’s Disease and Parkinson’s Disease. Aging Dis, 11:1-11.
[75] Zhang S, Zhi Y, Li F, Huang S, Gao H, Han Z, et al. (2018). Transplantation of in vitro cultured endothelial progenitor cells repairs the blood-brain barrier and improves cognitive function of APP/PS1 transgenic AD mice. J Neurol Sci, 387:6-15.
[76] Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016). Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev, 64:272-287.
[77] Santos CaY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J (2017). Pathophysiologic relationship between Alzheimer’s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 7:69-87.
[78] Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, et al. (2017). An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pr, 124:41-47.
[79] Degen C, Toro P, Schönknecht P, Sattler C, Schröder J (2016). Diabetes mellitus Type II and cognitive capacity in healthy aging, mild cognitive impairment and Alzheimer's disease. Psychiatry Res:42-46.
[80] Vieira MNN, Lima-Filho RAS, Felice FGD (2018). Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology, 136:160-171.
[81] Saraswati AP, Hussaini SMA, Krishna NH, Babu BN, Kamal A (2018). Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Eur J Med Chem, 144:843-858.
[82] Zhang Y, Huang N-q, Yan F, Jin H, Zhou S-y, Shi J-s, et al. (2018). Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res, 339:57-65.
[83] Kubis-Kubiak A, Rorbach-Dolata A, Piwowar A (2019). Crucial players in Alzheimer’s disease and diabetes mellitus: Friends or foes? Mechanisms of Ageing and Dev, 181:7-21.
[84] Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018). Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Res Clin Interventions, 4:575-590.
[85] Felice FGD, Lourenco MV, Ferreira ST (2014). How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s & Dementia, 10:S26-S32.
[86] Mushtaq G, Khan JA, Kumosani TA, Kamal MA (2015). Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci, 22:4-13.
[87] C Bir S, Y Chernyshev O, Minagar A (2018). Chapter 27-Roles of Toll-Like Receptors in Pathophysiology of Alzheimer’s Disease and Multiple Sclerosis. Neuroinflammation (Second Edition):541-562.
[88] Huang N-Q, Jin H, Zhou S-y, Shi J-s, Jin F (2017). TLR4 is a link between diabetes and Alzheimer’s disease. Behav Brain Res, 316:234-244.
[89] Velazquez R, Tran A, Ishimwe E, Denner L, Dave N, Oddo S, et al. (2017). Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer’s disease. Neurobiol Aging, 58:1-13.
[90] Shinohara M, Sato N (2017). Bidirectional interactions between diabetes and Alzheimer's disease. Neurochem Int, 108:296-302.
[91] Han C, Rice MW, Cai D (2016). Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am J Physiol Endocrinol Metab, 311:E32-E41.
[92] Muriach Ma, Flores-Bellver M, Romero FJ, Barcia JM (2014). Diabetes and the Brain: Oxidative Stress, Inflammation, and Autophagy. Oxid Med Cell Longev, 2014:1-9.
[93] Chen Y-L, Weng S-F, Yang C-Y, Wang J-J, Tien K-J (2019). Diabetic ketoacidosis further increases risk of Alzheimer’s disease in patients with type 2 diabetes. Diabetes Res Clin Pr, 147:55-61.
[94] Tang Y, Li Y-M, Zhang M, Chen Y-Q, Sun Q (2019). ε3/4 genotype of the apolipoprotein E is associated with higher risk of T Alzheimer's disease in patients with type 2 diabetes mellitus. Gene, 703:65-70.
[95] Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N (2010). Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis, 37:67-76.
[96] Mittal K, Katare DP (2016). Shared links between type 2 diabetes mellitus and Alzheimer’s disease: A review. Diabetes & Metabolic Syndrome: Clin Res Rev, 10S:S144-S149.
[97] Li J, Cesari M, Liu F, Dong B, Vellas B (2017). Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review. Can J Diabetes, 41:114-119.
[98] Clark LR, Berman SE, Rivera-Rivera LA, Hoscheidt SM, Darst BF, Engelman CD, et al. (2017). Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer’s disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 7:48-55.
[99] Gejl M, Gjedde A, Brock B, Møller A, Duinkerken Ev, Haahr HL, et al. (2018). Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial. Diabetologia, 61:551-561.
[100] Steculorum SM, Solas M, Brüning JC (2014). The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimer's & Dementia, 10:S3-S11.
[101] Assy MH, Awd M, Elshabrawy AM, Gharieb M (2019). Effect of Ramadan fasting on incidence of cerebrovascular stroke in Egyptian patients with Type 2 Diabetes Mellitus. Res Clin Pr, 151:299-304.
[102] Luitse MJA, Biessels GJ, Rutten GEHM, Kappelle LJ (2012). Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol, 11:261-271.
[103] Mangin G, Poittevin M, Charriaut-Marlangue C, Giannesini C, Merkoulova-Rainon T, Kubis N (2019). Glatiramer acetate reduces infarct volume in diabetic mice with cerebral ischemia and prevents long-term memory loss. Brain Behav Immun, 80:315-327.
[104] Filipov A, Ebert AD, Neumaier-Probst E, Alonso A (2018). The Burden of Diabetes and the Chance of a Previous Stroke: Thrombolysis for Recurrent Stroke in Diabetics. J Stroke Cerebrovascular Dis, 27:1343-1349.
[105] Chen R, Ovbiagele B, Feng W (2016). Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci, 351:380-386.
[106] Shimizu Y, Harashima A, Munesue S, Oishi M, Hattori T, Hori O, et al. (2020). Neuroprotective Effects of Endogenous Secretory Receptor for Advanced Glycation End-products in Brain Ischemia. Aging Dis, 11:1-12.
[107] Braun KF, Otter W, Sandor SM, Standl E, Schnell O (2012). All-cause in-hospital mortality and comorbidity in diabetic and non-diabetic patients with stroke. Diabetes Res Clinical Pr, 98:164-168.
[108] Alloubania A, Saleh A, Abdelhafiz I (2018). Hypertension and diabetes mellitus as a predictive risk factors for stroke. Diabetes & Metabolic Syndrome: Clin Res Rev, 12:577-584.
[109] Chen G, Wang X, Robinson TG, Pikkemaat M, Lindley RI, Zhou S, et al. (2018). Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial. J Neurol Sci, 387:1-5.
[110] Akhtar N, Kamran S, Singh R, Malik RA, Deleu D, Bourke PJ, et al. (2019). The Impact of Diabetes on Outcomes After Acute Ischemic Stroke: A Prospective Observational Study. J Stroke Cerebrovascular Dis, 28:619-626.
[111] Pan Y, Chen W, Wang Y (2019). Prediabetes and Outcome of Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis. J Stroke Cerebrovascular Dis, 28:683-692.
[112] Sun Y, Toh MPHS (2009). Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore. Value Health, 12:S101-S105.
[113] Elgebaly MM, Arreguin J, Storke N (2019). Targets, Treatments, and Outcomes Updates in Diabetic Stroke. J Stroke Cerebrovascular Dis, 28:1413-1420.
[114] Jun-Min C, Xiang-Jian Z, Xiao-Xia L, De-Gang S, Xiao-Yun C, Qian S (2018). Pericytes and Central Nervous System Diseases. Chin J Stroke, 13:90-95.
[115] Zhong W, Yuan Y, Gu X, Kim SI-y, Chin R, Loye M, et al. (2020). Neuropsychological Deficits Chronically Developed after Focal Ischemic Stroke and Beneficial Effects of Pharmacological Hypothermia in the Mouse. Aging Dis, 11:1-16.
[116] Yan W, Zhao X, Chen H, Zhong D, Jin J, Qin Q, et al. (2016). β-Dystroglycan cleavage by matrix metalloproteinase-2/-9 disturbs aquaporin-4 polarization and influences brain edema in acute cerebral ischemia. Neuroscience, 326:141-157.
[117] Villalba H, Shah K, Albekairi TH, Sifat AE, Vaidya B, Abbruscato TJ (2018). Potential role of myo-inositol to improve ischemic stroke outcome in diabetic mouse. Brain Res, 1699:166-176.
[118] Fuentes B (2018). Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist’s point of view. Medicina Clinica, 150:275-281.
[119] Rehni AK, Liu A, Perez-Pinzon MA, Dave KR (2017). Diabetic aggravation of stroke and animal models. Exp Neurol, 292:63-79.
[120] Boyko M, Zvenigorodsky V, Grinshpun J, Shiyntum HN, Melamed I, Kutz R, et al. (2019). Establishment of novel technical methods for evaluating brain edema and lesion volume in stroked rats: A standardization of measurement procedures. Brain Res, 1718:12-21.
[1] Schwartz Michael D,Emerson Stephen G,Punt Jennifer,Goff Willow D. Decreased Naïve T-cell Production Leading to Cytokine Storm as Cause of Increased COVID-19 Severity with Comorbidities[J]. Aging and disease, 2020, 11(4): 742-745.
[2] Yu Shimizu, Ai Harashima, Seiichi Munesue, Masahiro Oishi, Tsuyoshi Hattori, Osamu Hori, Yasuko Kitao, Hiroshi Yamamoto, Nontaphat Leerach, Mitsutoshi Nakada, Yasuhiko Yamamoto, Yasuhiko Hayashi. Neuroprotective Effects of Endogenous Secretory Receptor for Advanced Glycation End-products in Brain Ischemia[J]. Aging and disease, 2020, 11(3): 547-558.
[3] Iman Beheshti, Shiwangi Mishra, Daichi Sone, Pritee Khanna, Hiroshi Matsuda. T1-weighted MRI-driven Brain Age Estimation in Alzheimer’s Disease and Parkinson’s Disease[J]. Aging and disease, 2020, 11(3): 618-628.
[4] Seong Gak Jeon, Anji Yoo, Dong Wook Chun, Sang Bum Hong, Hyunju Chung, Jin-il Kim, Minho Moon. The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer’s Disease-related Pathogenesis[J]. Aging and disease, 2020, 11(3): 705-724.
[5] Xiaoheng Li, Yajin Liao, Yuan Dong, Shuoshuo Li, Fengchao Wang, Rong Wu, Zengqiang Yuan, Jinbo Cheng. Mib2 Deficiency Inhibits Microglial Activation and Alleviates Ischemia-Induced Brain Injury[J]. Aging and disease, 2020, 11(3): 523-535.
[6] Chin-Hsiao Tseng. Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone[J]. Aging and disease, 2020, 11(3): 658-667.
[7] Hong Liu, Shiyan Chen, Min Liu, Hao Nie, Hongyun Lu. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis[J]. Aging and disease, 2020, 11(3): 668-678.
[8] Yongming Jia, Na Wang, Yingbo Zhang, Di Xue, Haoming Lou, Xuewei Liu. Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance[J]. Aging and disease, 2020, 11(2): 390-404.
[9] Min Wu, Fali Li, Yuehao Wu, Tieying Zhang, Jian Gao, Peng Xu, Benyan Luo. Impaired Frontoparietal Connectivity in Traumatic Individuals with Disorders of Consciousness: A Dynamic Brain Network Analysis[J]. Aging and disease, 2020, 11(2): 301-314.
[10] Shawn Zheng Kai Tan, Man-Lung Fung, Junhao Koh, Ying-Shing Chan, Lee Wei Lim. The Paradoxical Effect of Deep Brain Stimulation on Memory[J]. Aging and disease, 2020, 11(1): 179-190.
[11] Yazhen Zhang, Wenyi Chen, Bing Feng, Hongcui Cao. The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis[J]. Aging and disease, 2020, 11(1): 141-153.
[12] Weiwei Zhong, Yan Yuan, Xiaohuan Gu, Samuel In-young Kim, Ryan Chin, Modupe Loye, Thomas A Dix, Ling Wei, Shan Ping Yu. Neuropsychological Deficits Chronically Developed after Focal Ischemic Stroke and Beneficial Effects of Pharmacological Hypothermia in the Mouse[J]. Aging and disease, 2020, 11(1): 1-16.
[13] Yanqing Wu, Libing Ye, Yuan Yuan, Ting Jiang, Xin Guo, Zhouguang Wang, Ke Xu, Zeping Xu, Yanlong Liu, Xingfeng Zhong, Junmin Ye, Hongyu Zhang, Xiaokun Li, Jian Xiao. Autophagy Activation is Associated with Neuroprotection in Diabetes-associated Cognitive Decline[J]. Aging and disease, 2019, 10(6): 1233-1245.
[14] Yanfang Zhao, Yuan Zhang, Lei Zhang, Yanhan Dong, Hongfang Ji, Liang Shen. The Potential Markers of Circulating microRNAs and long non-coding RNAs in Alzheimer's Disease[J]. Aging and disease, 2019, 10(6): 1293-1301.
[15] Xiuqin Jia, Zhijiang Wang, Tao Yang, Ying Li, Shuai Gao, Guorong Wu, Tao Jiang, Peipeng Liang. Entorhinal Cortex Atrophy in Early, Drug-naive Parkinson’s Disease with Mild Cognitive Impairment[J]. Aging and disease, 2019, 10(6): 1221-1232.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd